Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma

Blood Cancer J. 2015 Oct 23;5(10):e362. doi: 10.1038/bcj.2015.86.

Authors

H Saito¹, D Maruyama¹, A M Maeshima², S Makita¹, H Kitahara¹, K Miyamoto¹, S Fukuhara¹, W Munakata¹, T Suzuki¹, Y Kobayashi¹, H Taniguchi², K Tobinai¹

Affiliations

¹ Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bendamustine Hydrochloride / administration & dosage
Bendamustine Hydrochloride / adverse effects*
Female
Humans
Lymphoma, B-Cell / drug therapy*
Lymphoma, Mantle-Cell / drug therapy*
Lymphopenia / chemically induced*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Retrospective Studies
Rituximab / administration & dosage

Substances

Antineoplastic Agents, Alkylating
Rituximab
Bendamustine Hydrochloride